The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s showing significant promise in clinical trials for managing obesity. Unlike some available weight loss treatments, retatrutide appears to deliver a greater substantial loss in body size and enhance metabolic health, particularl